4D Molecular is attracting attention in the stock market with its upcoming Wet-AMD study readouts expected in 2027. This pivotal data could significantly impact the company's valuation and market position.
In addition to the Wet-AMD studies, 4D Molecular is also exploring expansion opportunities in Diabetic Macular Edema (DME), which could further enhance its growth prospects.
Analysts are optimistic about 4D Molecular's potential, recommending a 'Buy' rating based on the anticipated positive outcomes from the studies and the strategic expansion into DME.